Project Grant R01DA060226
Award Date
6/1/25
Completion Date
2/28/30
Dollars Obligated
$552K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK, USA
Similar Awards
This $982,800 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to leverage genome-wide and epigenome-wide association studies to better understand the relationship between nicotine metabolism, smoking cessation, and tobacco-related health outcomes in American Indian (AI) communities. The research project will be conducted by the University of Colorado-Denver and will involve a three-phased approach: 1)...
This $175,888 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop novel methods for studying the genetic and neurological mechanisms underlying nicotine and cannabis addiction. The key products and services to be delivered under this 4-year grant include: Developing a new Transcriptome-Wide Association Study (TWAS) method to identify genes associated with changes in brain functional connectivity...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $166,375 to The University of Kentucky Research Foundation to examine the impact of voluntary nicotine use on neurocognitive and neuroimmune consequences in a rodent model of HIV infection. The research aims to evaluate if chronic nicotine self-administration enhances cognitive function and anxiety-like behaviors, and how this relates to...
This federal Project Grant award, valued at $2,187,775.00 and issued on August 1, 2024, was provided by the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant aims to develop novel selective positive allosteric modulators (PAMs) of the high-sensitivity α4β2 nicotinic acetylcholine receptor (nAChR) subtypes, which are believed to play a key role in behaviors associated with nicotine dependence. The research will focus on synthesizing and...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $395,566 to support the development of a novel FDA-regulated pharmacotherapy for smoking cessation and nicotine de-addiction. The goal is to create a highly structured, multimodal nicotine cessation program with dramatically higher efficacy than current standard-of-care treatments. This Phase I proposal aims to fund the initial...
The National Institute on Drug Abuse (NIDA) awarded a $1,485,691 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Duke University to evaluate the neural correlates and behavioral impact of withdrawal-induced hyperalgesia among people who smoke with and without chronic pain. The key research objectives are to: 1) assess the impact of smoking withdrawal on brain activity in response to noxious heat stimuli, and 2) examine the influence of withdrawal-induced hyperalgesia on...
This $1,742,971 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the epigenetic regulation of inflammasome activation and its modulation by cannabinoids and antiretroviral therapy during chronic SIV infection and cocaine use. The primary objectives are to: 1) Examine the epigenetic mechanisms underlying cannabinoid-mediated reduction of cocaine-induced inflammasome...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to examine the impact of stress, mental health, and substance use disorders on the immune system of people living with HIV. The primary awardee, Yale University, will receive $1,790,186 over 5 years to conduct experimental studies and longitudinal assessments to determine how stress-related changes in the hypothalamic-pituitary-adrenal (HPA)...
This $742,352 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports a collaborative research effort focused on childhood adversity and multiple sclerosis (MS) health outcomes in high-risk minority populations. The 5-year grant, awarded to New York University School of Medicine, will develop culturally-sensitive research...
This $2,594,198 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to elucidate the role of the habenula (HB) brain region and its circuitry in tobacco use disorder (TUD). The grant, awarded to the University of California, Los Angeles (UCLA) with a sub-award to the University of Toronto, will use neuroimaging and genomic data from the UK Biobank to study HB functional connectivity with the...